Six Years of Acinetobacter Species in Critical Care: Carbapenem Resistance and Non-Susceptibility, Clinical Outcomes, and Lessons for Stewardship
Antibiotics · 04.03.2026 · 15 (3) · 267
DOI: 10.3390/antibiotics15030267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 04.03.2026. Verfasst von Mircea Stoian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Intensive Care, "George Emil Palade" University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe …. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș.
Abstract (Originalsprache)
Background
Acinetobacter spp., particularly A. baumannii, is a major intensive care unit (ICU) pathogen frequently associated with carbapenem non-susceptibility and delayed initiation of receipt of therapy.
Methods
We conducted a single-center retrospective ICU cohort study in Romania (January 2019–December 2024) of adults with clinical cultures positive for Acinetobacter spp. (first isolate per patient). Susceptibility was interpreted per EUCAST. We assessed species distribution, carbapenem non-susceptibility, receipt of at least one in vitro active empiric agent, time to active therapy (TTAT, from index culture collection), early inflammatory biomarkers [neutrophile-to-lymphocyte ratio (NLR) and C-reactive protein (CRP)], and 30-day mortality. Predictors of mortality were evaluated using multivariable logistic regression and receiver operating characteristic (ROC) analysis.
Results
A total of 234 episodes were included; A. baumannii accounted for 87.6% (205/234). Carbapenem non-susceptibility among Acinetobacter spp. isolates was 89.3% (209/234). Empiric antibiotics were initiated within 24 h in 95.7% of patients (224/234), yet only 49.6% (116/234) received at least one empiric agent later confirmed to be active. TTAT was 6 days (IQR 4–7), and active therapy within 72 h occurred in 8.5% (20/234). Thirty-day mortality was 73.1% (171/234) and did not differ between carbapenem non-susceptible (EUCAST I + R) and carbapenem-susceptible (EUCAST S) A. baumannii episodes (73.2% vs. 72.0%, p = 1.00). In multivariable analysis, age was independently associated with mortality (OR 1.36 per 10-year increase, 95% CI 1.04–1.90), with acceptable model discrimination (area under the curve = 0.74). Early NLR and CRP did not differ between carbapenem non-susceptible and carbapenem-susceptible A. baumannii episodes.
Conclusions
In this ICU cohort, A. baumannii was the predominant species, and carbapenem non-susceptibility was highly prevalent. Despite early empiric therapy, receipt of at least one in vitro active agent was often delayed, and early inflammatory biomarkers had limited discriminatory value. These findings support locally tailored empiric strategies informed by local epidemiology and reinforce the need for improved diagnostics and stewardship interventions in high-burden ICU settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesia and Intensive Care, "George Emil Palade" University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street No. 38, 540142 Târgu Mureș, Romania.
- Intensive Care Unit, Mures Clinical County Hospital, Street Gheorghe Marinescu No 1, 540103 Târgu Mureș, Romania.
- Faculty of Medicine, "George Emil Palade" University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street No. 38, 540142 Târgu Mureș, Romania.
- Gastroenterology Department, "George Emil Palade" University of Medicine, Pharmacy, Sciences and Technology of Târgu Mures, 540142 Târgu Mureș, Romania.
- Department of Radiology, "George Emil Palade" University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street No. 38, 540142 Târgu Mureș, Romania.
- Doctoral School of Medicine and Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, Gheorghe Marinescu Street No. 38, 540142 Târgu Mureș, Romania.
ORCID-Profile: Mircea Stoian, Andrei Claudiu Stângaciu, Danusia Onisor, Andrei Manea, Adrian Man, Adina Stoian
Förderung
- This work was supported by the George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș
- George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș
Zitieren
APA
Stoian, M., Azamfirei, L., Stângaciu, A. C., Manea, S., Onisor, D., Manea, A., Cora, A., Danilesco, A., Man, A., & Stoian, A. (2026). Six Years of Acinetobacter Species in Critical Care: Carbapenem Resistance and Non-Susceptibility, Clinical Outcomes, and Lessons for Stewardship. Antibiotics, 15(3), 267. https://doi.org/10.3390/antibiotics15030267
Vancouver
Stoian M, Azamfirei L, Stângaciu AC, Manea S, Onisor D, Manea A, et al. Six Years of Acinetobacter Species in Critical Care: Carbapenem Resistance and Non-Susceptibility, Clinical Outcomes, and Lessons for Stewardship. Antibiotics. 2026;15(3):267. doi:10.3390/antibiotics15030267
BibTeX
@article{Stoian2026,
author = {Stoian, Mircea and Azamfirei, Leonard and Stângaciu, Andrei Claudiu and Manea, Stefan and Onisor, Danusia and Manea, Andrei and Cora, Andrei and Danilesco, Alina and Man, Adrian and Stoian, Adina},
title = {Six Years of Acinetobacter Species in Critical Care: Carbapenem Resistance and Non-Susceptibility, Clinical Outcomes, and Lessons for Stewardship},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {3},
pages = {267},
doi = {10.3390/antibiotics15030267}
}
EUVIMED